%0 Journal Article
%T Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis
%A Carl R Flannery
%A Daniela Crandall
%A Helen Smith
%A Jane Fitzpatrick
%A Ross Leighton
%A Thierry Conrozier
%J Archive of "Open Access Rheumatology : Research and Reviews".
%D 2018
%R 10.2147/OARRR.S162127
%X Pain and limitations in joint mobility associated with knee osteoarthritis (OA) are clinically challenging to manage, and advanced progression of disease can often lead to total knee arthroplasty. Intra-articular injection of hyaluronic acid (HA), also referred to as viscosupplementation, is a non-surgical treatment approach for OA, the effectiveness of which may depend on the HA composition, and the length of time over which it resides in the joint. One of the available options for such therapies includes NASHA (Durolane HA), a non-animal, biofermentation-derived product, which is manufactured using a process that stabilizes the HA molecules to slow down their rate of degradation and produce a unique formulation with a terminal half-life of ~1 month. The objectives of the current review were to assess, in patients with OA of the knee, the efficacy and safety of intra-articular treatment with NASHA relative to control (saline) injections, other HA products, and other injectables (corticosteroids, platelet-rich plasma, mesenchymal stem cells)
%K osteoarthritis
%K viscosupplementation
%K intra-articular
%K hyaluronic acid
%K NASHA
%K Durolane
%K residence time
%K symptomatic relief
%K clinical outcomes
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967379/